361 related articles for article (PubMed ID: 17010686)
1. PPAR agonists modulate human osteoclast formation and activity in vitro.
Chan BY; Gartland A; Wilson PJ; Buckley KA; Dillon JP; Fraser WD; Gallagher JA
Bone; 2007 Jan; 40(1):149-59. PubMed ID: 17010686
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.
Hounoki H; Sugiyama E; Mohamed SG; Shinoda K; Taki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Miyahara T
Bone; 2008 Apr; 42(4):765-74. PubMed ID: 18242157
[TBL] [Abstract][Full Text] [Related]
3. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA
Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
[TBL] [Abstract][Full Text] [Related]
5. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Patel JJ; Butters OR; Arnett TR
Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
[TBL] [Abstract][Full Text] [Related]
6. Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes.
Kasonga A; Kruger MC; Coetzee M
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30979019
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast formation and bone resorption are inhibited by megakaryocytes.
Beeton CA; Bord S; Ireland D; Compston JE
Bone; 2006 Nov; 39(5):985-990. PubMed ID: 16870519
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
10. Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells.
Motokawa M; Tsuka N; Kaku M; Kawata T; Fujita T; Ohtani J; Matsuda Y; Terao A; Tanne K
Arch Oral Biol; 2013 Jan; 58(1):35-41. PubMed ID: 22771550
[TBL] [Abstract][Full Text] [Related]
11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
14. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia.
Olivier BJ; Schoenmaker T; Mebius RE; Everts V; Mulder CJ; van Nieuwkerk KM; de Vries TJ; van der Merwe SW
Hepatology; 2008 Jan; 47(1):259-67. PubMed ID: 18022900
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
16. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
17. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone induces bone resorption in human peripheral blood mononuclear cells.
Fuller K; Chambers TJ
Int J Exp Pathol; 1998 Aug; 79(4):223-33. PubMed ID: 9797718
[TBL] [Abstract][Full Text] [Related]
19. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts.
Perez-Amodio S; Beertsen W; Everts V
J Bone Miner Res; 2004 Oct; 19(10):1722-31. PubMed ID: 15355568
[TBL] [Abstract][Full Text] [Related]
20. Influence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fetal calf serum on human osteoclast formation and activity.
Kreja L; Liedert A; Schmidt C; Claes L; Ignatius A
J Mol Histol; 2007 Aug; 38(4):341-5. PubMed ID: 17576525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
